Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Oktober 2014

Planlagt Fastgjort Låst Flyttet Genmab
1.0k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • investor1989I Offline
    investor1989I Offline
    investor1989
    wrote on sidst redigeret af
    #661

    +6% er længe siden vi sidst har set

    1 Reply Last reply
    0
    • SolsenS Offline
      SolsenS Offline
      Solsen
      wrote on sidst redigeret af
      #662

      +4% på c20 indeks ?

      1 Reply Last reply
      0
      • SolsenS Offline
        SolsenS Offline
        Solsen
        wrote on sidst redigeret af
        #663

        Er væksten kommet til Europa ?

        1 Reply Last reply
        0
        • J Offline
          J Offline
          JKY_VH
          wrote on sidst redigeret af
          #664

          Det er bare mig der er kommet hjem fra ferie:-)

          1 Reply Last reply
          0
          • C Offline
            C Offline
            cpi
            wrote on sidst redigeret af
            #665

            tja, det luk i us bliver vi vist ikke klogere af, hælder mest til, vi skal ned på mandag, måske en 3-5 kr.

            1 Reply Last reply
            0
            • SolsenS Offline
              SolsenS Offline
              Solsen
              wrote on sidst redigeret af
              #666

              Jeg synes den er helt umulig at spå om...

              1 Reply Last reply
              0
              • investor1989I Offline
                investor1989I Offline
                investor1989
                wrote on sidst redigeret af
                #667

                Revlimid det 10 dyreste lægemiddel pr. patient i verden: http://www.fiercepharma.com/special-reports/top-10-most-expensive-drugs-2013 Alexions lægemiddel klart dyrest

                1 Reply Last reply
                0
                • BudweisB Offline
                  BudweisB Offline
                  Budweis
                  wrote on sidst redigeret af
                  #668

                  Dette interview William R. Strohl (VP hos Janssen) er ret interessant - http://www.bizjournals.com/philadelphia/blog/health-care/2014/08/why-the-next-big-biologic-may-be-found-by-montco.h
                  tml

                  1 Reply Last reply
                  0
                  • BudweisB Offline
                    BudweisB Offline
                    Budweis
                    wrote on sidst redigeret af
                    #669

                    Just a moment...

                    favicon

                    (www.bizjournals.com)

                    1 Reply Last reply
                    0
                    • BudweisB Offline
                      BudweisB Offline
                      Budweis
                      wrote on sidst redigeret af
                      #670

                      Strohl said one of the difficulties in developing bispecific antibodies is overcoming manufacturing hurdles. “Most can’t be manufactured,” he said. “I have to say we were a little frustrated that we couldn’t develop, internally, a technology that could be trusted to be manufacturable.”

                      Genmab’s technology proved to be the most promising solution. “We now have 20 bispecific licenses with them,” Strohl said.

                      1 Reply Last reply
                      0
                      • J Offline
                        J Offline
                        JKY_VH
                        wrote on sidst redigeret af
                        #671

                        Tak for info Budweis.

                        1 Reply Last reply
                        0
                        • S Offline
                          S Offline
                          Sukkeralf
                          wrote on sidst redigeret af
                          #672

                          Ja meget opmuntrende læsning. Kunne Janssen så ikke lige også nappe en aftale på hexabody.

                          1 Reply Last reply
                          0
                          • G Offline
                            G Offline
                            gentogen
                            wrote on sidst redigeret af
                            #673

                            Open Monoclonal Technology, Inc. (OMT), an innovator of novel genetic engineering of animals for creation of human therapeutic antibodies, today announced an alliance with Genmab A/S (OMX: GEN), a biotechnology company specializing in human antibody therapeutics. The deal gives Genmab unlimited access to OMT’s three OmniAb™ platforms, OmniRat®, OmniMouse® and OmniFlic™

                            1 Reply Last reply
                            0
                            • G Offline
                              G Offline
                              gentogen
                              wrote on sidst redigeret af
                              #674

                              Open Monoclonal Technology, Inc. (OMT) is a leader in genetic engineering of animals for creation of human therapeutic antibodies, naturally optimized human antibodies®, and the only company in the world with three transgenic animal platforms

                              1 Reply Last reply
                              0
                              • G Offline
                                G Offline
                                gentogen
                                wrote on sidst redigeret af
                                #675

                                OMT has granted unlimited platform access to Genmab, Genentech, Janssen, Merck KGaA, Pfizer, Roche, Symphogen

                                1 Reply Last reply
                                0
                                • investor1989I Offline
                                  investor1989I Offline
                                  investor1989
                                  wrote on sidst redigeret af
                                  #676

                                  Genmab vil have adgang til flere antistoffer som de kan kombinere i duobody

                                  1 Reply Last reply
                                  0
                                  • celsiusC Offline
                                    celsiusC Offline
                                    celsius
                                    wrote on sidst redigeret af
                                    #677

                                    Det Europæiske Lægemiddelagentur har godkendt lægemidlet Imbruvica (ibrutinib) fra Janssen og partneren Pharmacyclics til to indikationer inden for behandling af blodkræft. Markedet skærpes nu for alvor for Genmab. Er der nogen der ønsker at kommentere på det ? I artiklen står der at Imbrutinib skulle være i fase 3 kombi med Arzerra .. har det sin rigtighed ?

                                    1 Reply Last reply
                                    0
                                    • celsiusC Offline
                                      celsiusC Offline
                                      celsius
                                      wrote on sidst redigeret af
                                      #678

                                      Citat MedWatch i dag: ”Det store Genmab-håb er, at man succesfuldt kan kombinere Arzerra med Imbruvica. I øjeblikket er den kombinationsbehandling i fase 3, efter selvsamme kombination tidligere har vist særdeles stærke data i et mindre fase 2-studie”

                                      1 Reply Last reply
                                      0
                                      • S Offline
                                        S Offline
                                        Sukkeralf
                                        wrote on sidst redigeret af
                                        #679

                                        Vi er ikke i fase III her, men det har været på tegnebrættet !!

                                        1 Reply Last reply
                                        0
                                        • S Offline
                                          S Offline
                                          Sukkeralf
                                          wrote on sidst redigeret af
                                          #680

                                          Man er i fase III med Zydelig - og de resultater ser vi vel på ASH

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger